TRINITY BIOTECH PLC Form SCHEDULE 13D/A — Nov 10, 2026
Perceptive Advisors and affiliates (including Joseph Edelman) amended their Schedule 13D on Trinity Biotech to disclose that on November 6, 2026 the parties entered into a Fifth Amendment to the credit agreement, a Second Amended and Restated Convertible Note, and warrant amendments. The reporting group beneficially owns 54,148,590 Class A Ordinary Shares, a 9.99% stake based on 487,879,340 shares outstanding. The Fifth Amendment includes a limited waiver of Trinity Biotech's minimum liquidity covenant for June through October 2026 — the company disclosed it was not in compliance for June, July and August 2026 — plus an additional $4.0 million term loan borrowing.
Key figures
- Debt Amount
- 4000000
- Shares Owned
- 54148590
- Percent Owned
- 9.99
- Shares Outstanding
- 487879340
- Conversion cap
- 72500000
- Floor price new
- $10.00 per ADS
- Floor price prior
- $15.183 per ADS
- Liquidity covenant
- $1,000,000 through Sep 2026; $3,000,000 thereafter
- Warrant exercise price
- $5.90 per ADS
- Beneficial ownership cap
- 9.9% (note/conversions) and 9.99% (warrants)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.